Cancer Epigenomics, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS/SERGAS), Santiago de Compostela, Spain.
Roche-Chus Joint Unit, Translational Medical Oncology Group (Oncomet), Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.
Adv Exp Med Biol. 2020;1220:117-134. doi: 10.1007/978-3-030-35805-1_8.
Liquid biopsy based on the analysis of circulating tumor cells (CTCs) has emerged as an important field of research. Molecular characterization of CTCs can provide insights into cancer biology and biomarkers for the clinic, representing a non-invasive powerful tool for monitoring breast cancer metastasis and predict the therapeutic response. Epigenetic mechanisms play a key role in the control of gene expression and their alteration contributes to cancer development and progression. These epigenetic modifications in CTCs have been described mainly related to modifications of the DNA methylation pattern and changes in the expression profile of noncoding RNAs. Here we summarize the recent findings on the epigenetic characterization of CTCs in breast cancer and their clinical value as tumor biomarkers, and discuss challenges and opportunities in this field.
液体活检基于循环肿瘤细胞(CTCs)的分析已经成为一个重要的研究领域。CTC 的分子特征可以提供癌症生物学的深入了解和临床的生物标志物,代表了一种非侵入性的强大工具,用于监测乳腺癌转移和预测治疗反应。表观遗传机制在基因表达的控制中起着关键作用,其改变有助于癌症的发展和进展。这些在 CTC 中发生的表观遗传修饰主要与 DNA 甲基化模式的改变和非编码 RNA 表达谱的变化有关。在这里,我们总结了最近关于乳腺癌 CTC 表观遗传特征及其作为肿瘤标志物的临床价值的研究结果,并讨论了该领域的挑战和机遇。